Purpose: The purpose of this case report is to bring to light this unusual combination of two rare diseases, namely Neimann-Pick disease Type B and clear cell chondrosarcoma occurring in the same patient. This has not previously been reported in the world literature. Subject: Niemann-Pick disease (NPD) is a rare autosomal recessive inborn error of metabolism. Type B NPD is even rarer. It is a lysosomal storage disorder affecting children and adolescents often causing death in early childhood, although in milder form patients may survive up to adulthood, like our patient. Clear cell chondrosarcoma is a very rare type of chondrosarcoma affecting the epiphyseo-metaphyseal region of long bones. We present a patient suffering from a milder form of Neimann Pick disease who developed a clear cell chondrosarcoma. We investigated to find if there was likely to be any relationship between these two events. Results: NPD type B is caused by a three-base deletion in chromosome 11. Chondrosarcoma and multiple exostoses occur due to loss of tumour suppressor gene EXT 2 from centromeric region on chromosome 11, though it is difficult to establish the link between the two, as the two together have not yet been reported in the literature. NPD may present diagnostic difficulties when it occurs with chondrosarcoma. Discussion: We conclude that the two diseases have not been reported together in the world literature and there is some evidence to show that chromosome 11 is central to both diseases. More research is needed to see if one leads to the other.
Introduction
Niemann-Pick disease (NPD) is a rare autosomal recessive inborn error of metabolism, a lysosomal storage disorder characterized by deficiency of acid sphingomyelinase. Acid sphingomyelinase is an enzyme metabolising cell membrane lipid sphingomyelin. This leads to sphingomyelin deposition in the lysosomes of cells in brain, reticuloendothelial and lung tissue [1] . Chondrosarcoma is a rare slowgrowing malignant tumour of bone producing cartilage matrix, common in the the fifth and sixth decades [2] . These two diseases have not been reported together as patients with NPD usually die early and chondrosarcoma is common after the fifth decade.
Case report
A 50-year-old right-handed maintenance engineer presented with a 4-week history of left elbow pain. It was initially diagnosed as tennis elbow but no X-rays were taken. He later sustained a pathological fracture of his left olecranon while opening a door ( Figure 1 ). This fracture was internally fixed by the referring hospital but a sample taken at the time of surgery revealed a chondrosarcoma and hence he was sent to the oncology service at our hospital.
He had a history of NPD as a child and had splenomegaly and interstitial lung disease but otherwise had no signs of manifestation of the disease.
Examination of his left elbow showed a range of 30-90 of flexion with full supination and pronation. Neurovascular status of the left upper limb was normal. Magnetic resonance imaging of his left elbow showed an effusion in the joint and not much else due to the implant. Computer tomography and bone scintiagraphy showed no evidence of metastases.
The patient opted for an above elbow amputation because of the high risk of local recurrence with limb salvage surgery especially in view of the intraarticular disease and previous surgery. Histology of the amputated limb showed a grade II conventional chondrosarcoma mixed with foci of clear cell chondrosarcoma of the left proximal ulna with wide amputation margins ( Figure 2 ). The patient has subsequently developed multiple lung metastases.
Results
We did a literature search to understand the nature of the two diseases, probed if there were any genetic link between the two and if one can influence the presentation, progression and prognosis of the other. NPD type B is caused by delta 608 mutation, a threebase deletion in chromosome 11 that causes the removal of an arginine residue from position 608 of the ASM polypeptide [3] . Chondrosarcoma and multiple exostoses occur due to loss of tumour suppressor gene EXT 2 from centromeric region on chromosome 11 by base deletion as one of the mechanism [4] , though it is difficult to establish the link between the two with available research in molecular genetics. Though we could not prove that one can influence the progression and prognosis of the other, certainly NPD produces interstitial lung disease which could present diagnostic difficulties in ruling out pulmonary metastases by imaging, as happened in our patient where initially diagnosed interstitial lung disease in the follow-up CT proved to be lung secondaries from chondrosarcoma ( Figures 3 and 4) .
Discussion
NPD is an inborn error of metabolism, leading to deposition of lipid in the lysosomes of cells [1, 5] . Histologically large pale foamy cells are seen in the reticuloendothelial system, which stain positively with lipid stains. The gene for acid sphingomyelinase is carried on chromosome 11, mutations of which cause decreased production of the active enzyme [3, 6] .
There are three types of NPD. Type A disease has less than 5% of active enzyme, and is a rapidly progressive neurodegenerative disease of infancy manifested by failure to thrive, severe psychomotor retardation, feeding problems, progressive spasticity, blindness with cherry red spot, hepato-splenomegaly, jaundice of infancy with progressive liver failure and death. Most patients die by the age of 2-3 years.
Type C is also a severe form and due to defective cholesterol transport, trapping sphingomyelin and cholesterol inside cells with central nervous system involvement leading to seizures and death by 5-15 years of age.
Type B, as seen in this case, is a milder form with 5-10% of acid sphingomyelinase activity and patients live up to late childhood and adulthood, like our patient. It is characterised by reticuloendothelial system sphingomyelin deposition leading to hepatosplenomegaly and pulmonary involvement with an absence of neurological manifestation and survival into adulthood [6, 7] . Diagnosis of NPD is by enzyme assay of acid sphingomyelinase from peripheral blood WBCs or from cultured skin fibroblasts. Prenatal diagnosis by amniocentesis is possible. At present most of the available treatments are preventive [8] , supportive or experimental. These include enzyme replacement therapy, gene therapy, and bone marrow transplant. Chondrosarcoma is a rare malignant bone tumour producing cartilage matrix common in the fifth and sixth decade with a male to female ratio of 3:2. Our patient had a clear cell chondrosarcoma with associated classical grade II chondrosarcoma. Clear cell chondrosarcoma is also called 'malignant chondroblastoma'. It represents about 2% of malignant cartilaginous bone tumours with a male to female ratio of 3:2. It commonly affects the proximal femur or tibia and only rarely the ulna. Histologically it shows sheet-like non-lobular arrangement of cartilaginous cells with tumour cells showing abundant clear cytoplasm and distinct cell borders due to paucity of organelles and a cytosol with low protein content in these cells. The presence of a spectrum of immature chondroblasts to mature chondrocytes is characteristic of clear cell chondrosarcoma.
Radiologically it shows as an ephiphyseal osteolytic and expansile lesion. More than 50% of these tumours do not show calcification. As soft tissue invasion is rare this tumour has a good prognosis. A combination of clear cell and classical chondrosarcoma is not uncommon, whilst dedifferentiated clear cell chondrosarcoma has also been reported [10] .
The treatment of chondrosarcoma is usually surgical with wide local excision. Radiotherapy and chemotherapy are not effective. If the tumour is incompletely excised it has a high incidence of local recurrence and subsequent metastasis [11, 12] .
It was difficult to prove that one leads to the other, though more research in molecular genetics probing this problem may well establish a link in the future. Although chondrosarcoma is associated with altered carbohydrate metabolism [12] , we could not prove that one can influence the progression and prognosis of the other; however, NPD does produce interstitial lung disease, which could present diagnostic difficulties in ruling out pulmonary metastases. With the presently available evidence, the two diseases arising together appears to be a chance occurrence.
